Clinical status of diagnosis and therapy of malignant melanoma

F. Belli, M. Santinami, M. T. Baldini, A. Testori, A. Maio, N. Cascinelli

Research output: Contribution to journalArticle

Abstract

We believe that the immunotherapy of melanoma represents a fundamental approach in the treatment of this disease. In this regard the monoclonal antibodies, because of their high specificity, their demonstrated lack of toxicity after repeated injection and the possibility of their use both as direct cytotoxic factors and carriers of other molecules, constitute one of the most intriguing prospectives of therapy of this threatening cancer.

Original languageEnglish
Pages (from-to)621-624
Number of pages4
JournalNuclear Medicine and Biology
Volume16
Issue number6
Publication statusPublished - 1989

Fingerprint

Melanoma
Immunotherapy
Monoclonal Antibodies
Injections
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Belli, F., Santinami, M., Baldini, M. T., Testori, A., Maio, A., & Cascinelli, N. (1989). Clinical status of diagnosis and therapy of malignant melanoma. Nuclear Medicine and Biology, 16(6), 621-624.

Clinical status of diagnosis and therapy of malignant melanoma. / Belli, F.; Santinami, M.; Baldini, M. T.; Testori, A.; Maio, A.; Cascinelli, N.

In: Nuclear Medicine and Biology, Vol. 16, No. 6, 1989, p. 621-624.

Research output: Contribution to journalArticle

Belli, F, Santinami, M, Baldini, MT, Testori, A, Maio, A & Cascinelli, N 1989, 'Clinical status of diagnosis and therapy of malignant melanoma', Nuclear Medicine and Biology, vol. 16, no. 6, pp. 621-624.
Belli, F. ; Santinami, M. ; Baldini, M. T. ; Testori, A. ; Maio, A. ; Cascinelli, N. / Clinical status of diagnosis and therapy of malignant melanoma. In: Nuclear Medicine and Biology. 1989 ; Vol. 16, No. 6. pp. 621-624.
@article{09ed6379d0e24693a38bb056946ff84b,
title = "Clinical status of diagnosis and therapy of malignant melanoma",
abstract = "We believe that the immunotherapy of melanoma represents a fundamental approach in the treatment of this disease. In this regard the monoclonal antibodies, because of their high specificity, their demonstrated lack of toxicity after repeated injection and the possibility of their use both as direct cytotoxic factors and carriers of other molecules, constitute one of the most intriguing prospectives of therapy of this threatening cancer.",
author = "F. Belli and M. Santinami and Baldini, {M. T.} and A. Testori and A. Maio and N. Cascinelli",
year = "1989",
language = "English",
volume = "16",
pages = "621--624",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Clinical status of diagnosis and therapy of malignant melanoma

AU - Belli, F.

AU - Santinami, M.

AU - Baldini, M. T.

AU - Testori, A.

AU - Maio, A.

AU - Cascinelli, N.

PY - 1989

Y1 - 1989

N2 - We believe that the immunotherapy of melanoma represents a fundamental approach in the treatment of this disease. In this regard the monoclonal antibodies, because of their high specificity, their demonstrated lack of toxicity after repeated injection and the possibility of their use both as direct cytotoxic factors and carriers of other molecules, constitute one of the most intriguing prospectives of therapy of this threatening cancer.

AB - We believe that the immunotherapy of melanoma represents a fundamental approach in the treatment of this disease. In this regard the monoclonal antibodies, because of their high specificity, their demonstrated lack of toxicity after repeated injection and the possibility of their use both as direct cytotoxic factors and carriers of other molecules, constitute one of the most intriguing prospectives of therapy of this threatening cancer.

UR - http://www.scopus.com/inward/record.url?scp=0024443440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024443440&partnerID=8YFLogxK

M3 - Article

C2 - 2691455

VL - 16

SP - 621

EP - 624

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 6

ER -